Pregabalin was brought to market by Pfizer in 2002.
 Pregabalin also closely resembles the -amino acids L-leucine and L-isoleucine, and this may be of greater relevance in relation to its pharmacodynamics than its structural similarity to GABA
 Pregabalin is a gabapentinoid and acts by inhibiting certain calcium channels

